JORDEN DAVID EMERSON 4

What Happened JORDEN DAVID EMERSON (listed in the filing), who serves as CEO/CFO and a director of Nuo Therapeutics, received an award/acquisition of 13,245 shares on 2026-06-05. The reported weighted-average price for the shares is $1.10, for a total reported value of $14,506. This transaction is an acquisition/award (code A) rather than a sale.

Key Details

• Transaction date: 2026-06-05
• Transaction type: Award/Grant/Other acquisition (Code A)
• Shares acquired: 13,245 shares
• Reported weighted-average price: $1.10; actual trades ranged from $1.042 to $1.15 per share (footnote F1)
• Reported total value: $14,506
• Shares owned after the transaction: Not specified in the provided Form 4 excerpt
• Timeliness: Filing date equals transaction date (2026-06-05), so the Form 4 appears timely
• Footnote F1: Price is a weighted average across multiple transactions; the reporting person offers to provide a breakdown of purchases by price upon request.

Context This was an acquisition/award (likely part of compensation or a grant) rather than an open-market purchase or option exercise. Such awards are common for executives; they reflect receipt of company stock but do not by themselves indicate a purchase motivated by a view on the stock. The dollar amount here (~$14.5k) is relatively small for an executive-level award.